Neoleukin Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Neurogene

04/08/2023 16:01

* Neoleukin Therapeutics Inc  NLTX.OQ   NLTX.O  is expected
to show no change in quarterly revenue when it reports 
results on August 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Neoleukin
Therapeutics
Inc is for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $1.5​, above​ its last closing price
of $0.67. ​​​

This summary was machine generated August 4 at 15:01 GMT.  All
figures in US dollars  unless otherwise stated